PEB
24/06/2015 08:33
FLLYR
PRICE SENSITIVE
REL: 0833 HRS Pacific Edge Limited
FLLYR: PEB: Adjustment to Pacific Edge's Preliminary Financial Results
24 June 2015
ADJUSTMENT TO PACIFIC EDGE'S PRELIMINARY FINANCIAL RESULTS
Pacific Edge advises that an adjustment has been made to its financial
statements for the year ended 31st March 2015, to include a provision for the
payment of up to $500,000 for the settlement reached with the FMA as
announced on the 25th of May. A provision was not included in the
preliminary results announced on the 28th of May due to the timing of the
decision with the FMA and the release of the preliminary results three days
later.
The company remains focused on driving awareness and commercial sales of its
Cxbladder tests in all of its targeted markets.
This adjustment increases the Net Loss for the period to $11.229m from the
reported $10.729m.
Pacific Edge's full financial results will be released on the 29th of June
2015.
For more information contact:
David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800
ABOUT Cxbladder Triage
Cxbladder Triage is a novel molecular test that combines the power of the
genomic biomarkers with extra phenotypic and clinical risk factors to
accurately identify and remove patients with hematuria who have a low
probability of bladder cancer, from needing to have a full-urological
work-up. This is a tool for use by clinicians and physicians in the primary
evaluation and is intended to reduce of the number of patients needing an
expensive and invasive work-up for urothelial cancer.
www.cxbladder.com
ABOUT Cxbladder Detect
Cxbladder Detect is a proprietary, accurate molecular diagnostic test that
enables the non-invasive detection of bladder and other urinary tract cancers
from a small volume of urine. Cxbladder Detect is commercially available in
New Zealand, Australia and the USA. Cxbladder Detect is available in the USA
and NZ as a Laboratory Developed Test (LDT) from the company's CLIA certified
laboratories, providing physicians and clinicians with a quick, cost
effective and accurate measure of the presence of the cancer, and provides
urologists with an effective adjunct to cystoscopy. The Cxbladder Detect
cancer detection test has been validated by a multi-centre, international
clinical study.
www.cxbladder.com
ABOUT Bladder Cancer
Globally, bladder cancer has the 9th highest incidence and the 4th highest
incidence for men. One of the early symptoms of bladder cancer is the
presence of blood in the urine, haematuria. People with haematuria often
present to their general practitioner before being referred on to a
urologist. Bladder cancer has a very high recurrence rate of approximately
50%-70% with up to 30% of these recurring as later stage tumours. However,
bladder cancers are highly treatable, especially if detected in the early
stages when there is a much higher probability of survival. Timely detection
and regular surveillance and monitoring of this cancer is a key element of
the clinical process and of the individual's annual healthcare plan.
ABOUT Pacific Edge
Pacific Edge Limited (NZX: PEB) is a New Zealand based cancer diagnostic
company specialising in the discovery and commercialisation of diagnostic and
prognostic technology for the early detection and monitoring of cancer. The
company is developing and commercialising its range of Cxbladder bladder
cancer tests. It's first commercial product, Cxbladder Detect, is now being
actively marketed to physicians and clinicians in New Zealand, Australia, and
the USA through the company's wholly owned subsidiaries and selected
commercial partners.
www.pacificedge.co.nz www.pacificedgedx.com
End CA:00266073 For:PEB Type:FLLYR Time:2015-06-24 08:33:40
